TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
15 hedge funds and large institutions have $2.81M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
35% less funds holding
Funds holding: 23 → 15 (-8)
63% less capital invested
Capital invested by funds: $7.57M → $2.81M (-$4.76M)
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$74.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$41.8K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$35K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$10.1K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$2.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Puissance Capital Management
New York
|
-$1.26M |
| 2 |
6CM
683 Capital Management
New York
|
-$410K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$219K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
-$65K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$43K |
TCON Hedge Fund Activity: Q4 2019 in Review
15 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q4 2019, worth a combined $2.81M — down 63% from $7.57M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TCON and 2 opened new positions — a net loss of 8 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $74.7K. The largest seller was Puissance Capital Management, cutting an estimated $1.26M.
- 15 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q4 2019, down from 23 in Q3 2019.
- Funds reported $2.81M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q4 2019, down 63% quarter-over-quarter.
- 2 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q4 2019 and 10 closed out, a net change of -8 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q4 2019 was Renaissance Technologies, an estimated $74.7K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q4 2019 was Puissance Capital Management, an estimated $1.26M sold.
Based on aggregated 13F filings for Q4 2019.